Drug Trial Radar · NCT02477826
An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Last checked: Nov 19, 2026Latest source record: Oct 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,747
Actual
Start
Aug 5, 2015
Primary completion
Oct 25, 2024
Study completion Oct 25, 2024
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- Collaborators
- Ono Pharmaceutical Co., Ltd.
- First posted
- Jun 23, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to show that Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus Platinum-Doublet Chemotherapy improves progression free survival and/or overall survival compared with chemotherapy in patients with advanced lung cancer.
Conditions
- Non-Small Cell Lung Cancer
Interventions
NivolumabDrug
IpilimumabDrug
CarboplatinDrug
CisplatinDrug
GemcitabineDrug
PemetrexedDrug
PaclitaxelDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival Per BICRTime frame: From randomization untill disease progression or death, whichever occurs first (up to approximately 481 weeks)
- Overall SurvivalTime frame: From randomization untill death or last follow up whichever occurs first (up to approximately 481 weeks)
Locations
290 sites in 33 countries. Site status is shown where the registry gives one.
Southern Cancer Center, Inc.
Mobile, Alabama
Local Institution - 0017
San Francisco, California
Local Institution - 0021
New Haven, Connecticut
Local Institution - 0001
Atlanta, Georgia
Local Institution - 0013
Marietta, Georgia
Local Institution - 0004
Lexington, Kentucky
Local Institution - 0115
St Louis, Missouri
Local Institution - 0005
Buffalo, New York
Local Institution - 0019
New York, New York
Local Institution - 0014
Cleveland, Ohio
Local Institution - 0009
Columbus, Ohio
Local Institution - 0007
Allentown, Pennsylvania
Local Institution - 0075
Langhorne, Pennsylvania
Local Institution - 0299
Philadelphia, Pennsylvania
Local Institution - 0012
Philadelphia, Pennsylvania
Local Institution - 0015
Sayre, Pennsylvania
Local Institution - 0008
Charleston, South Carolina
Local Institution - 0080
Greenville, South Carolina
Local Institution - 0010
Greenville, South Carolina
Local Institution - 0020
Nashville, Tennessee
Local Institution - 0306
Dallas, Texas
Local Institution - 0003
Dallas, Texas
Local Institution - 0102
Houston, Texas
Local Institution - 0011
Salt Lake City, Utah
Local Institution - 0074
Kennewick, Washington
Local Institution - 0268
Córdoba, Argentina
Local Institution - 0272
Córdoba, Argentina
Local Institution - 0297
Córdoba, Argentina
Local Institution - 0177
Viedma, Argentina
Local Institution - 0170
Berazategui, Buenos Aires, Argentina
Local Institution - 0171
Capital Federal, Buenos Aires, Argentina
Local Institution - 0172
Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina
Local Institution - 0176
Ciudad de Buenos Aires, Buenos Aires, Argentina
Local Institution - 0296
Mar del Plata, Buenos Aires, Argentina
Local Institution - 0130
San Miguel de Tucumán, Tucumán Province, Argentina
Local Institution - 0040
Murdoch, Australia
Local Institution - 0183
North Tamworth, Australia
Local Institution - 0182
Garran, Australian Capital Territory, Australia
Local Institution - 0301
Blacktown, New South Wales, Australia
Local Institution - 0300
Gosford, New South Wales, Australia
Showing 40 of 290 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.